News | June 15, 2012

Endosense Completes Enrollment in FDA Study of Force-Sensing Ablation Catheter

June 15, 2012 —Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study. TOCCASTAR is a prospective, randomized, multi-center investigational device exemption (IDE) trial designed to evaluate the safety and effectiveness of the company’s TactiCath force-sensing ablation catheter in patients with symptomatic paroxysmal atrial fibrillation (AF).

TOCCASTAR study investigators enrolled 300 patients at 17 centers across the United States and Europe. All patients were randomized on a one-to-one basis for treatment with the TactiCath or a control radiofrequency catheter approved by the U.S. Food and Drug Administration (FDA) for treating paroxysmal AF.

The TOCCASTAR study will evaluate the safety and effectiveness of the TactiCath based on 12-month follow-up data from the index procedure. The primary effectiveness endpoint is a non-inferiority comparison of treatment success as defined by both acute procedural success and chronic freedom from symptomatic paroxysmal AF, atrial tachycardia and atrial flutter; the safety endpoint is a non-inferiority comparison of early onset device-related serious adverse events. Secondary endpoints include a superiority comparison of procedural effectiveness related to the use of the contact-force sensor.

“Contact-force sensing in the context of a radiofrequency ablation catheter represents a significant enhancement to the tools available to electrophysiologists treating AF. The idea that we can deliver intra-cardiac lesions will full knowledge of the quality of the electrode-tissue interface is very appealing,” said Vivek Reddy, M.D. TOCCASTAR principal investigator and director of the Cardiac Arrhythmia Service, The Mount Sinai Medical Center, New York. “When complete, TOCCASTAR will provide the first randomized comparison of treatment safety and success between a conventional radiofrequency catheter and one with contact-force sensing capability. Through the use of this important diagnostic feature, we are gaining singular insights into the challenges and techniques that define optimal cardiac ablation therapy.”

Endosense expects to use the results of the TOCCASTAR study to support a premarket approval application (PMA) to the FDA in the third quarter of 2013.

 


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now